What is the current Price Target for the Gain Therapeutics Inc stock?

The average Gain Therapeutics Inc target price is $8.00. This is 406.33% higher than the current stock price. The highest price target is 659.49%, the lowest is 216.46%. 7 Analysts have issued a price target Gain Therapeutics Inc 2026 .

How high will the Gain Therapeutics Inc stock rise?

No reliable answer can be given as to how high the Gain Therapeutics Inc stock will rise. The performance of stocks, including the Gain Therapeutics Inc stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Gain Therapeutics Inc stock today?

The performance of Gain Therapeutics Inc stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Gain Therapeutics Inc stock fall?

The decline in Gain Therapeutics Inc stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Gain Therapeutics Inc Forecast, price target & analysts

$1.56

5.45% yesterday

Nasdaq, Apr 10, 09:50 pm CET

ISIN

US36269B1052

Symbol

GANX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Gain Therapeutics Inc Target price 2025 - Analyst rating & recommendation

Gain Therapeutics Inc Classifications & Recommendation:

Buy

100%

Gain Therapeutics Inc Price Target

Target Price	$8.00
Price	$1.58
Potential	406.33% register free of charge
Number of Estimates	7

	7 Analysts have issued a price target Gain Therapeutics Inc 2026 . The average Gain Therapeutics Inc target price is $8.00. This is 406.33% register free of charge higher than the current stock price. The highest price target is $12.00 659.49% register free of charge , the lowest is $5.00 216.46% register free of charge .
	A rating was issued by 7 analysts: 7 Analysts recommend Gain Therapeutics Inc to buy, 0 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Gain Therapeutics Inc stock has an average upside potential 2026 of 406.33% register free of charge . Most analysts recommend the Gain Therapeutics Inc stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Dec '24	2025 Estimates
Earnings Per Share $	-0.89	-0.65
	47.95%	26.97%
P/E		negative

2 Analysts have issued a Gain Therapeutics Inc forecast for earnings per share. The average Gain Therapeutics Inc EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2024. The highest EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2024	$-0.89	47.95%
2025	$-0.65 26.97% Unlock
2026	$-0.63 3.08% Unlock
2027	$-0.92 46.03% Unlock
2028	$-0.91 1.09% Unlock
2029	$0.01 101.10% Unlock

Current	-1.65	20.67%
2025	-2.43 47.27% Unlock
2026	-2.51 3.29% Unlock
2027	-1.72 31.47% Unlock
2028	-1.74 1.16% Unlock
2029	158.00 9,180.46% Unlock

Gain Therapeutics Inc...

Current Gain Therapeutics Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
Chardan Capital	Locked ➜ Locked	Locked	Mar 28 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Mar 17 2025
Scotiabank	Locked ➜ Locked	Locked	Mar 07 2025
Roth MKM	Locked ➜ Locked	Locked	Dec 24 2024
Roth MKM	Locked ➜ Locked	Locked	Dec 05 2024
HC Wainwright & Co.	Locked ➜ Locked	Locked	Nov 25 2024
HC Wainwright & Co.	Locked ➜ Locked	Locked	Oct 09 2024

Analyst Rating	Date
Locked Chardan Capital: Locked ➜ Locked	Mar 28 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Mar 17 2025
Locked Scotiabank: Locked ➜ Locked	Mar 07 2025
Locked Roth MKM: Locked ➜ Locked	Dec 24 2024
Locked Roth MKM: Locked ➜ Locked	Dec 05 2024
Locked HC Wainwright & Co.: Locked ➜ Locked	Nov 25 2024
Locked HC Wainwright & Co.: Locked ➜ Locked	Oct 09 2024

Discover more stocks with a high price target

Novo Nordisk 90.54%

MongoDB 78.62%

TUI 68.73%

Coinbase Global, Inc. 67.18%

Infineon 60.61%

NIO ADR 59.99%

NVIDIA 57.87%

Alibaba Group Holding Ltd 52.22%

BioNTech SE - ADR 50.44%

Walt Disney 48.21%

PayPal 47.01%

Adyen 45.04%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now